CoSyne Therapeutics’ Post

Rachel Watkins is Director of Experimental Biology at CoSyne Therapeutics, a company working on creating a platform for drug discovery in under-served brain diseases, based on high-quality scientific data integrated with AI and machine learning. We all know the saying ‘garbage in, garbage out’ so CoSyne have concentrated on generating the highest quality, clinically relevant data for their platform. Focusing initially on astroglial diseases, including aggressive brain cancers, CoSyne aim to develop a model that can aid drug discovery for brain diseases and beyond. Working from a biobank of patient-derived tumour cell lines, cells are grown in 3D culture to mimic tumour conditions as closely as possible e.g. hypoxia gradient. These cells are then characterised through whole-genome sequencing, single-cell transcriptomics and CRISPRi screens and these data used to power AI generated cellular simulations in order to identify biomarker / target pairings. To verify their platform’s efficiency CoSyne have identified biomarker/target pairings already established in the literature as well as many novel targets. This work has shown that the platform is working well and CoSyne are currently looking at re-purposing phase I safe but de-prioritised therapeutics towards new indications to accelerate the path of new treatments for patients in need. Rachel will be speaking at Drug Discovery 2024 on Thursday 3 October in the track ‘Target discovery and disease modelling’. Register now to catch her talk at Drug Discovery 2024: https://lnkd.in/ePmtmfN9 #braincancer #CRISPR #braindisease #singlecellsequencing #singlecell #therapeutics #cancer #tumor #braintumor #genomics #wholegenomesequencing #transcriptomics